Review Volume 10, Issue 12 pp 4248—4268

Figure 1. Recommendations for the treatment of newly diagnosed patients with Waldenstrom’s Macroglobulinemia. Figure adjusted from ESMO guidelines for WM 2018 and EMN recommendations for treatment of rare plasma cell dyscrasias. *Approved in USA by FDA for first line and only for patients unfit for immunochemotherapy in Europe by EMA. ** BR for unfit patients may require dose reductions for bendamustine and use of G-CSF and antibiotic prophylaxis. BDR: bortezomib, dexamethasone, rituximab, BR: bendamustine, rituximab; DRC: dexamethasone, rituximab, cyclophosphamide; AF: atrial fibrillation, V: bortezomib.